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Abstract
The first national guideline on palliative sedation in The Netherlands has been adopted by
the General Board of the Royal Dutch Medical Association. By law, the physician is obliged to
take this guideline into consideration. In this paper, we present the main principles of the
guideline. Palliative sedation is defined as the intentional lowering of consciousness of
a patient in the last phase of his or her life. The aim of palliative sedation is to relieve
suffering, and lowering consciousness is a means to achieve this. The indication for
palliative sedation is the presence of one or more refractory symptoms that lead to unbearable
suffering for the patient. Palliative sedation is given to improve patient comfort. It is the
degree of symptom control, not the level to which consciousness is lowered, which determines
the dose and the combinations of the sedatives used and duration of treatment. Palliative
sedation is normal medical practice and must be clearly distinguished from the termination of
life. J Pain Symptom Manage 2007;34:666e670.  2007 U.S. Cancer Pain Relief
Committee. Published by Elsevier Inc. All rights reserved.
Key Words
Palliative sedation, guidelineIntroduction
Over the past few years, a great deal of dis-
cussion has taken place in The Netherlands
about ‘‘terminal sedation,’’ also known as palli-
ative sedation. The discussion was about the
criteria and the conditions that must be met,
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tive sedation and euthanasia. In 2003, the for-
mer Chief Prosecutor, Joan De Wijkerslooth,
suggested that terminal sedation should per-
haps be covered by the Euthanasia Act. Minis-
ter Piet Hein Donner and Secretary of State
Cle´mence Ross-van Dorp responded by in-
forming the Lower House that terminal seda-
tion was normal medical practice.1
In the third study of medical decisions in
end-of-life care, published in 2003, data on ter-
minal sedation appeared for the first time.2 In
its reaction to this study, the government
stressed that it was important for the medical
profession itself to develop a national
0885-3924/07/$esee front matter
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September 2004, at the request of the Ministry
of Health, Welfare and Sports, the Royal Dutch
Medical Association (RDMA) appointed a com-
mittee that was given the task of drawing up
this guideline. The committee consisted of
a medical ethicist (chairperson), two medical
oncologists, two general practitioners, two
nursing home physicians, one anesthesiologist,
two nurses, a health lawyer, and a health scien-
tist. All authors of this paper were members of
the RDMA committee that designed the
guideline.
The committee met 11 times between Octo-
ber 2004 and September 2005. A literature re-
view was performed. After a consensus was
reached within the committee and a draft
guideline was written, comments were given
by several medical, nursing, and pharmacist as-
sociations, medical ethicists, and the Ministry
of Justice. In November 2005, the final version
of the guideline was adopted by the General
Board of the RDMA.3 By implication, the
guideline is now part of the physician’s profes-
sional standard(s). By law, the physician is ob-
liged to act according to these standard(s).
On December 7, 2005, the guideline was of-
fered to the Secretary of State for Health, Wel-
fare and Sports.
There are a limited number of guidelines or
recommendations for clinical practice.4e14
One of these was recently published as a na-
tional guideline,10 some were developed at
an institutional level by a specific task
force,5,9,13 and others reflect the opinion and
experience of the authors.4,6e8,11,12,14 Re-
cently, recommendations for standards for pal-
liative sedation were published by a task force
of the European Association for Palliative
Care.15 In this paper, we present the main prin-
ciples of the guideline.
What Is Palliative Sedation?
The terms palliative sedation, sedation in
the final phase of life, terminal sedation, or
deep sedation may have different meanings,
but are often used as synonyms. In the guide-
line, the term ‘‘palliative sedation’’ is pre-
ferred, as it makes quite clear that this
sedation takes place in the framework of palli-
ative care. Several definitions have beenproposed in the literature.15e19 The definition
of palliative sedation used in the guideline is as
factual as possible; palliative sedation is ‘‘the
intentional lowering of consciousness of a pa-
tient in the last phase of his or her life.’’ The
objective of palliative sedation is to relieve suf-
fering (caused by refractory, i.e., untreatable,
symptoms), and lowering consciousness is
a means to achieve this. It is very important
that palliative sedation is given for the right in-
dication, proportionally and adequately.
Proportionally means that consciousness is
lowered only to the level necessary and suffi-
cient to achieve the desired level of symptom
alleviation.14,15,17,20 The level of reduction of
consciousness to achieve this end may vary
from superficial to deep. The assessment and
decision-making processes must focus on ade-
quate relief of the patient’s suffering, so that
a peaceful and acceptable situation is created.
Palliative sedation is given in the last phase of
life, in the imminently dying patient.
According to the guideline, palliative seda-
tion may be used in two ways: 1) continuous
sedation until death or 2) short-term or inter-
mittent sedation. The ethical, legal, social,
and political debate that has taken place re-
garding ‘‘terminal sedation’’ was mainly about
continuous sedation until death.
Indication and Conditions
As in all other guidelines,4e15 the indication
for palliative sedation is formulated as follows:
the presence of one or more refractory symp-
toms, which leads to unbearable suffering for
the patient. A symptom is or becomes refrac-
tory if none of the conventional treatments
are effective (within a reasonable time frame)
and/or these treatments are accompanied by
unacceptable side effects.6,15 Pain, dyspnea,
and delirium are the most common refractory
symptoms that in clinical practice lead to the
use of palliative sedation.5,6,15,17
Another condition (which only applies to
deep and continuous sedation until death) is
that death must be expected within one to
two weeks.4,18 This condition is also men-
tioned in other guidelines.5,8,10,13e15 In the
guideline, the assumption is made that if
deep and continuous sedation is administered
(and the patient is, therefore, unable to take
668 Vol. 34 No. 6 December 2007Verkerk et al.fluids him- or herself), artificial hydration will
not contribute to the relief of suffering4,15,21,22
and may, in fact, have disadvantages, such as
the need for a subcutaneous or intravenous
cannula and the possible increase of some
symptoms and signs (e.g., pain, edema, bron-
chial secretion, and urinary incontinence). Al-
though the decision to discontinue or not to
start artificial hydration should be seen as a sep-
arate decision,15 the guideline recommends in
general not to give fluids to a deeply sedated
patient. It should be noted in this regard that
almost all patients for whom deep palliative se-
dation is considered have already stopped tak-
ing fluids prior to sedation. If life expectancy is
less than two weeks, it is assumed that with-
drawing artificial hydration will not hasten
death. If life expectation is longer, the situa-
tion is different, because in that case, the pa-
tient would die sooner due to dehydration
than would otherwise be the case.
Decision Making
In a situation of severe suffering caused by
refractory symptoms, palliative sedation may
come up for discussion as the result of a
requestdexplicitly or implicitlydfrom the pa-
tient and/or his or her family. Health care pro-
fessionals also may take the initiative. In the
guideline, it is stated that consideration of pal-
liative sedation demands an exploration of the
patient’s situation. Relevant information
should be obtained from the patient, the fam-
ily, and the health care providers involved; this
should lead to an adequate assessment of the
patient’s condition. Continuity of teamwork,
good coordination, exchange of information,
and communication between the various care
providers are essential. Lack of any of these
may lead to inadequate assessment, informa-
tion discrepancies, and to unrest. Optimal
agreement between all those involved, espe-
cially in the home situation, is crucial.
Eventually, this should lead to a decision by
the physician responsible for the treatment.
Palliative sedation is regarded as a normal
medical procedure, although one used rarely
and only under exceptional circumstances. El-
ements of the decision are the aim and level
(superficial or deep) of the sedation, choice
of the correct medication, and dosage. Notes
on the decision-making process and theconsiderations playing a role in it are to be re-
corded in the patient’s file, including any con-
sultation that has taken place with the patient
and/or his or her family, between the care pro-
viders, and with any specialists involved. In
case of disagreement between the medical
team and the relatives about what is in the pa-
tient’s best interest, the doctor has the final say
in the decision making (as is regulated in sec-
tion 465 of the Dutch Patients’ Rights Act).
In acute life-threatening (e.g., acute suffoca-
tion due to tumor growth or bleeding) situa-
tions, the treating physician may decide to
initiate palliative sedation without consulta-
tion. In these cases, the steps referred to above
must then be carried out after starting
sedation.
Consultation
Just as in all other forms of medical treat-
ment, there must always be sufficient expertise
on which to base the decision to initiate palli-
ative sedation. A doctor who is responsible
but has insufficient knowledge of the treat-
ment of severe symptoms, is uncertain about
the correctness of the indication, and/or has
insufficient knowledge on how to administer
sedatives should consult an expert, preferably
a palliative care specialist.4,5,7,9e11,13e15
Administering Sedation
The initiation of palliative sedation is an
emotionally charged occasion, especially if it
leads to a rapid loss of consciousness so that
communication with the patient is lost. The
doctor should be present when it is initiated,
because sometimes intervention is necessary.
In the subsequent phase, the administration
of sedation can be left largely to nurses and
carers, if necessary.
In the guideline, the administration or dose
increasing of opioids or other nonprimarily
sedative medications with the implicit or ex-
plicit objective of producing sedation is re-
garded as improper use of these medications,
as sedation may occur at doses that may be as-
sociated with undesirable effects, and even
high doses may fail to induce sedation.4,15,18,22
When palliative sedation is started, usually
a stepwise approach is taken. Midazolam is
the drug of first choice. If the response to an
optimal dose of midazolam is inadequate, the
Vol. 34 No. 6 December 2007 669A National Guideline for Palliative Sedationteam should check that the route of adminis-
tration and the medication are in order and
whether any reversible interfering factors
(such as a full bladder or constipation) are
playing a role. Only after excluding these fac-
tors should drugs such as levomepromazine,
phenobarbital, or propofol be considered.
Other Aspects
Good documentation is essential. The rele-
vant data about the patient and his or her situ-
ation must be recorded in the file: why the
decision was made to initiate palliative seda-
tion, how it was administered, an assessment
of its effect, and what criteria must be met to
adjust the dosage. The treating physician
should visit the patient at least once a day.
Optimal palliative care also includes giving
attention, support, and counseling to the pa-
tient’s family and close friends. Both during
the course of events leading up to palliative se-
dation and during its administration, they play
an important role. They function as carers, ob-
servers, informants, and representatives of the
patient, in addition to their role as partner,
family member, close friend, or acquaintance.
They go through their own process of uncer-
tainty, feelings of guilt, fear, sorrow, and
mourning. Giving information and explana-
tions to the family, working with them, and as-
sessing the situation with them are essential for
a satisfactory procedure and good parting.
There should also be attention for the team
members involved: care for the carers.
Throughout the whole process, care and sup-
port should be available for the various care
providers who are involved in the patient’s sit-
uation. This requires good communication,
reflection, and support for care providers.
Palliative Sedation and Euthanasia
In the period preceding the appearance of
the guideline, discussion took place about
the position of continuous sedation until
death in comparison to life-terminating treat-
ment, in particular, euthanasia. The guideline
expresses the view that palliative sedation is
normal medical practice and must be clearly
distinguished from the termination of life.
Palliative sedation is a way to reduce con-
scious experience of symptoms and, therefore,of severe suffering. Palliative sedation differs
from euthanasia in that palliative sedation is
not aimed at the termination of life. There is
no evidence that appropriately administered
palliative sedation shortens life.23 This means
that palliative sedation and euthanasia must
be clearly distinguished from each other. Palli-
ative sedation is for patients who do not want
to suffer any more but do not want to end their
lives either. This means that palliative sedation
that is administered for the correct indication,
in the correct dose, and in an adequate way is
not a ‘‘shortcut’’ to achieving the same goal as
euthanasia, namely to end life, but more slowly
and without observing the requirements and
procedures set for euthanasia. Palliative seda-
tion is not ‘‘slow euthanasia.’’24e26
Conclusion
Initially, palliative sedation had been associ-
ated with the termination of life. It should
not be. There is no evidence that proportional-
ly administered palliative sedation shortens
life. In recent years, it has been stressed
more and more often that palliative sedation
is normal medical practice. This view is the
point of departure in the new guideline issued
by the RDMA. Nevertheless, it is still important
to define explicit criteria and conditions for
the use of palliative sedation in order to con-
tribute to sound medical practice in this area.
It is in this light that the contents of the guide-
line should be seen. In this guideline, the com-
mittee has gathered current knowledge and
experience based on several previously exist-
ing regional guidelines, the national and inter-
national literature and the opinions of experts
within and outside the committee. Advancing
insights will undoubtedly lead to adjustments
in the guideline. For the time being, it is im-
portant that the debate about palliative seda-
tion is stripped of spurious elements and that
physicians and other care providers are aware
of the standards and points of departure for
sound practice.
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